CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of...

CERo Therapeutics Announces Research Collaboration with Lyell Immunopharma and Completion of Series A Financing -- Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors -- -- $40 Million Raised by CERo to Facilitate Preclinical and Clinical Development -- SOUTH SAN...